title: Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes.
abstract: The regulation of cardiac and vascular function by the alpha 1B- and alpha 1D-adrenoceptors (ARs) has been assessed in two lines of transgenic mice, one over-expressing a constitutively active alpha 1B-AR mutation (alpha 1B-ARC128F) and the other an alpha 1D-AR knockout line. The advantage of using mice expressing a constitutively active alpha 1B-AR is that the receptor is tonically active, thus avoiding the use of nonselective agonists that can activate all subtypes. In hearts from animals expressing alpha 1B-ARC128F, the activities of the mitogen-activated protein kinases, extracellular signal-regulated kinase, and c-Jun N-terminal kinase were significantly elevated compared with nontransgenic control animals. Mice over-expressing the alpha 1B-ARC128F had echocardiographic evidence of contractile dysfunction and increases in chamber dimensions. In isolated-perfused hearts or left ventricular slices from alpha 1B-ARC128F-expressing animals, the ability of isoproterenol to increase contractile force or increase cAMP levels was significantly decreased. In contrast to the prominent effects on the heart, constitutive activation of the alpha 1B-AR had little effect on the ability of phenylephrine to induce vascular smooth muscle contraction in the isolated aorta. The ability of phenylephrine to stimulate coronary vasoconstriction was diminished in alpha 1D-AR knockout mice. In alpha 1D-AR knockout animals, no negative effects on cardiac contractile function were noted. These results show that the alpha1-ARs regulate distinctly different physiologic processes. The alpha 1B-AR appears to be involved in the regulation of cardiac growth and contractile function, whereas the alpha 1D-AR is coupled to smooth muscle contraction and the regulation of systemic arterial blood pressure.
authors.affiliation: Department of Molecular and Biomedical Pharmacology, The University of Kentucky College of Medicine, Lexington, KY 40536-0084, USA.
authors.forename: Dan
authors.initials: D
authors.lastname: Chalothorn
authors.forename: Dan F
authors.initials: DF
authors.lastname: McCune
authors.forename: Stephanie E
authors.initials: SE
authors.lastname: Edelmann
authors.forename: Kimimasa
authors.initials: K
authors.lastname: Tobita
authors.forename: Bradley B
authors.initials: BB
authors.lastname: Keller
authors.forename: Robert D
authors.initials: RD
authors.lastname: Lasley
authors.forename: Dianne M
authors.initials: DM
authors.lastname: Perez
authors.forename: Akito
authors.initials: A
authors.lastname: Tanoue
authors.forename: Gozoh
authors.initials: G
authors.lastname: Tsujimoto
authors.forename: Ginell R
authors.initials: GR
authors.lastname: Post
authors.forename: Michael T
authors.initials: MT
authors.lastname: Piascik
mesh_terms: D000322:Adrenergic Agonists / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D010477:Perfusion; D010656:Phenylephrine / Q000494:pharmacology; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: C547717:Adra1b protein, mouse; C547720:Adra1d protein, mouse; D000322:Adrenergic Agonists; D018340:Receptors, Adrenergic, alpha-1; D010656:Phenylephrine; D000242:Cyclic AMP; D020928:Mitogen-Activated Protein Kinases